| pubmed-article:1549645 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1549645 | lifeskim:mentions | umls-concept:C0025260 | lld:lifeskim |
| pubmed-article:1549645 | lifeskim:mentions | umls-concept:C0442038 | lld:lifeskim |
| pubmed-article:1549645 | lifeskim:mentions | umls-concept:C0036442 | lld:lifeskim |
| pubmed-article:1549645 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1549645 | lifeskim:mentions | umls-concept:C0069772 | lld:lifeskim |
| pubmed-article:1549645 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:1549645 | pubmed:dateCreated | 1992-4-22 | lld:pubmed |
| pubmed-article:1549645 | pubmed:abstractText | The effects exerted by oxiracetam on the disruption of performance induced by scopolamine in the radial arm maze were investigated in overtrained rats. Scopolamine induced a dose-related decrease in the efficiency of responding and an increase of running time. The effect of the SC injection of 0.2 mg/kg scopolamine on the efficiency of responding was antagonized by the IP administration of 30 mg/kg oxiracetam, while the effect on running time induced by the same dose of scopolamine was not. Physostigmine (0.3 mg/kg SC) antagonized both effects of 0.2 mg/kg scopolamine. Methylscopolamine, at the dose of 0.2 mg/kg SC, was devoid of any effect on both parameters. Increasing the dose of methylscopolamine to 0.63 mg/kg did cause serious peripheral effects which eventually prevented some animals from completing the task. Similar peripheral effects were observed after administration of 0.63 mg/kg scopolamine. The effects of this dose of scopolamine on efficiency and running time were not antagonized by pretreatment with 100 mg/kg oxiracetam. Oxiracetam alone (30 or 100 mg/kg IP) did not modify the performance of previously trained rats. The present results suggest that oxiracetam selectively restores cholinergic mechanisms which are involved in learning and memory. | lld:pubmed |
| pubmed-article:1549645 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1549645 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1549645 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1549645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1549645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1549645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1549645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1549645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1549645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1549645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1549645 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1549645 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1549645 | pubmed:issn | 0033-3158 | lld:pubmed |
| pubmed-article:1549645 | pubmed:author | pubmed-author:DorigottiLL | lld:pubmed |
| pubmed-article:1549645 | pubmed:author | pubmed-author:MagnaniMM | lld:pubmed |
| pubmed-article:1549645 | pubmed:author | pubmed-author:PozziOO | lld:pubmed |
| pubmed-article:1549645 | pubmed:author | pubmed-author:BanfiSS | lld:pubmed |
| pubmed-article:1549645 | pubmed:author | pubmed-author:BiagettiRR | lld:pubmed |
| pubmed-article:1549645 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1549645 | pubmed:volume | 106 | lld:pubmed |
| pubmed-article:1549645 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1549645 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1549645 | pubmed:pagination | 175-8 | lld:pubmed |
| pubmed-article:1549645 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:meshHeading | pubmed-meshheading:1549645-... | lld:pubmed |
| pubmed-article:1549645 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1549645 | pubmed:articleTitle | Oxiracetam antagonizes the disruptive effects of scopolamine on memory in the radial maze. | lld:pubmed |
| pubmed-article:1549645 | pubmed:affiliation | ISF Laboratories for Biomedical Research, Milano, Italy. | lld:pubmed |
| pubmed-article:1549645 | pubmed:publicationType | Journal Article | lld:pubmed |
